Eagle Swats More Vasopressin Hurdles As Petition And Injunction Are Denied
FDA Intends To Refer Par Citizen Petition To US Federal Trade Commission
In a clean sweep for Eagle Pharmaceuticals, following its recent approval for the first generic version of Par’s Vasostrict, the ANDA sponsor has seen defeated a Par citizen petition and dodged injunctive action launched by the Endo subsidiary.
You may also be interested in...
Eagle management provided detailed insight into the existing market for vasopressin, which it entered in January with the first generic version of Endo’s Vasostrict. The US-based player believes operating cash flows for the year, boosted also by its Pemfexy (pemetrexed) launch, could top $170m, paving the way for a major acquisition.
Eagle Pharmaceuticals has celebrated a US court ruling that clears the way for it to launch its generic vasopressin rival to Endo’s Vasostrict. However, the company is still waiting for FDA approval after its application was delayed by a CRL earlier this year, with a new action date provided by the agency.
Eagle Pharmaceuticals was gearing up for patent-litigation proceedings with Endo over Vasostrict on 1 February but has quickly seen the landscape shift.